India Surges in Clinical Trials, Overtaking Japan

India is significantly expanding its role in the Asia-Pacific clinical trial landscape, overtaking Japan in trial initiations during 2024. This surge is largely attributed to the country's growing number of contract development and manufacturing organizations that foster partnerships and provide funding. India's appeal is further amplified by its cost efficiencies and access to a substantial patient population, making it a prime location for clinical research.

The nation's large and highly educated workforce presents a key advantage, with salary costs considerably lower than in Western countries. This allows for greater resource allocation, enabling companies to hire more personnel, such as clinical research coordinators, for the same budget. Consequently, India is becoming an attractive region for regulatory purposes, ensuring clinical study populations are representative of global therapeutic targets.